Zomedica Corp. [AMEX: ZOM] gained 8.73% on the last trading session, reaching $2.49 price per share at the time. The company report on March 8, 2021 that Zomedica Retires Preferred Shares.
TRUFORMA® Progressing Toward Commercialization.
Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it has effected the exchange of all of its outstanding Series 1 Preferred Shares for its common shares and that it continues to progress with its planned commercialization of its TRUFORMA® platform.
Zomedica Corp. represents 972.02 million in outstanding shares, while the company has a total market value of $2.16 billion with the latest information. ZOM stock price has been found in the range of $2.32 to $2.59.
If compared to the average trading volume of 176.23M shares, ZOM reached a trading volume of 102726874 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Zomedica Corp. [ZOM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZOM shares is $1.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZOM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Zomedica Corp. is set at 0.32 The Price to Book ratio for the last quarter was 27.67, with the Price to Cash per share for the same quarter was set at 0.07.
Trading performance analysis for ZOM stock
Zomedica Corp. [ZOM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.45. With this latest performance, ZOM shares dropped by -6.39% in over the last four-week period, additionally plugging by 2209.83% over the last 6 months – not to mention a rise of 1455.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 64.42, with the RSI for the last a single of trading hit 67.84, and the three-weeks RSI is set at 63.64 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 1.55, while it was recorded at 2.19 for the last single week of trading, and 0.49 for the last 200 days.
Zomedica Corp. [ZOM]: A deeper dive into fundamental analysis
Return on Total Capital for ZOM is now -50.05, given the latest momentum, and Return on Invested Capital for the company is -51.08. Return on Equity for this stock declined to -51.94, with Return on Assets sitting at -48.09. When it comes to the capital structure of this company, Zomedica Corp. [ZOM] has a Total Debt to Total Equity ratio set at 2.96. Additionally, ZOM Total Debt to Total Capital is recorded at 2.88, with Total Debt to Total Assets ending up at 2.82. Long-Term Debt to Equity for the company is recorded at 2.13, with the Long-Term Debt to Total Capital now at 1.68.
Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 31.00 and a Current Ratio set at 31.00.
Zomedica Corp. [ZOM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Zomedica Corp. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZOM.
An analysis of insider ownership at Zomedica Corp. [ZOM]
There are presently around $110 million, or 6.70% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 19,340,445, which is approximately 79.474% of the company’s market cap and around 4.42% of the total institutional ownership; CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., holding 12,254,080 shares of the stock with an approximate value of $30.51 million in ZOM stocks shares; and BLACKROCK INC., currently with $21.06 million in ZOM stock with ownership of nearly New of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 23 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 20,262,520 shares. Additionally, 17 investors decreased positions by around 4,856,670 shares, while 6 investors held positions by with 22,921,707 shares. The mentioned changes placed institutional holdings at 48,040,897 shares, according to the latest SEC report filing. ZOM stock had 15 new institutional investments in for a total of 9,016,014 shares, while 10 institutional investors sold positions of 1,398,017 shares during the same period.